Your browser is no longer supported. Please, upgrade your browser.
Settings
DFFN Diffusion Pharmaceuticals Inc. daily Stock Chart
DFFN [NASD]
Diffusion Pharmaceuticals Inc.
Index- P/E- EPS (ttm)-3.92 Insider Own- Shs Outstand10.52M Perf Week7.64%
Market Cap23.14M Forward P/E- EPS next Y- Insider Trans- Shs Float6.72M Perf Month-15.38%
Income-40.50M PEG- EPS next Q- Inst Own2.80% Short Float4.80% Perf Quarter-24.91%
Sales- P/S- EPS this Y31.30% Inst Trans5.37% Short Ratio1.99 Perf Half Y-52.69%
Book/sh-1.85 P/B- EPS next Y- ROA-174.60% Target Price89.30 Perf Year-76.96%
Cash/sh1.16 P/C1.90 EPS next 5Y- ROE- 52W Range1.80 - 15.50 Perf YTD-2.65%
Dividend- P/FCF- EPS past 5Y64.30% ROI- 52W High-85.81% Beta-0.35
Dividend %- Quick Ratio0.40 Sales past 5Y- Gross Margin- 52W Low22.22% ATR0.23
Employees10 Current Ratio0.40 Sales Q/Q- Oper. Margin- RSI (14)46.30 Volatility14.43% 10.10%
OptionableNo Debt/Eq- EPS Q/Q-345.90% Profit Margin- Rel Volume2.33 Prev Close2.14
ShortableYes LT Debt/Eq- EarningsMay 15 Payout- Avg Volume162.15K Price2.20
Recom2.00 SMA20-3.24% SMA50-13.97% SMA200-40.25% Volume377,195 Change2.80%
Jul-21-17 08:00AM  Today's Research Reports on Trending Tickers: Diffusion Pharmaceuticals Inc. and Juno Therapeutics Inc. Accesswire
Jul-20-17 08:30AM  Diffusion Pharmaceuticals Achieves Drug Production Milestone For Planned Phase 3 Clinical Trial In Inoperable GBM Brain Cancer GlobeNewswire +10.31%
Jul-06-17 08:00AM  Diffusion Pharmaceuticals Appoints Dr. Robert Ruffolo to Board of Directors GlobeNewswire
May-26-17 10:00AM  Diffusion Pharmaceuticals to Present at the 7th Annual LD Micro Invitational Accesswire
May-25-17 12:00PM  DFFN: Focusing on Inoperable GBM Patients for Phase 3 Trial of TSC Zacks Small Cap Research
May-15-17 04:05PM  Diffusion Pharmaceuticals Provides Corporate Highlights and Reports Financial First Quarter 2017 Results GlobeNewswire
Apr-07-17 12:00PM  DFFN: Phase 3 Trial of TSC in GBM to Initiate in 2017 Zacks Small Cap Research -7.57%
Apr-04-17 08:41AM  Diffusion Pharmaceuticals Awarded U.S. Patent for TSC as Therapeutic in Five Hypoxia-Related Indications GlobeNewswire +12.01%
08:41AM  Diffusion Pharmaceuticals Awarded U.S. Patent for TSC as Therapeutic in Five Hypoxia-Related Indications
Apr-03-17 08:40AM  DIFFUSION PHARMACEUTICALS INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of E -10.28%
08:30AM  Diffusion Pharmaceuticals Announces Closing of Oversubscribed Private Placement GlobeNewswire
Mar-31-17 04:25PM  DIFFUSION PHARMACEUTICALS INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statement +10.83%
11:58AM  DIFFUSION PHARMACEUTICALS INC. Files SEC form 10-K, Annual Report
08:30AM  Diffusion Pharmaceuticals Provides Corporate Highlights and Reports 2016 Financial Results GlobeNewswire
Mar-29-17 09:30AM  Diffusion Pharmaceuticals Gets Professional Recognition and Akers Biosciences Achieves a First Accesswire -26.51%
Mar-15-17 09:10AM  DIFFUSION PHARMACEUTICALS INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of E
Feb-08-17 11:35AM  Wednesdays Biggest Biopharma Movers 24/7 Wall St.
11:35AM  Wednesdays Biggest Biopharma Movers
08:00AM  Diffusion Pharmaceuticals TSC Phase 1/2 Glioblastoma Multiforme Clinical Trial Results Published in February 2017 Edition of Journal of Neurosurgery GlobeNewswire
Jan-27-17 06:14AM  DIFFUSION PHARMACEUTICALS INC. Files SEC form 8-K/A, Regulation FD Disclosure, Financial Statements and Exhibits
Jan-26-17 03:52PM  DIFFUSION PHARMACEUTICALS INC. Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, R -6.33%
Jan-12-17 09:30AM  Latest Reports on Diffusion and Merrimack as Drug Stocks are Hit by President Trump's Comments Accesswire -6.33%
Jan-10-17 10:42AM  This Small-Cap Rotation Is Unconvincing TheStreet.com +46.49%
10:42AM  This Small-Cap Rotation Is Unconvincing
Jan-09-17 04:34PM  DIFFUSION PHARMACEUTICALS INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders +176.70%
Dec-12-16 08:30AM  Diffusion Pharmaceuticals Files Definitive Proxy Statement for Upcoming Special Meeting of Stockholders GlobeNewswire
Nov-19-16 01:04PM  DIFFUSION PHARMACEUTICALS INC. Financials
Nov-14-16 11:30AM  DIFFUSION PHARMACEUTICALS INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statement
08:00AM  Diffusion Pharmaceuticals Provides Corporate Highlights and Reports Financial Third Quarter 2016 Results GlobeNewswire
Nov-08-16 11:02AM  DIFFUSION PHARMACEUTICALS INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statement
08:00AM  Diffusion Pharmaceuticals Announces Uplisting to NASDAQ Capital Market GlobeNewswire
Oct-13-16 04:45PM  DIFFUSION PHARMACEUTICALS INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements an
Jun-08-16 06:07PM  Diffusion Pharmaceuticals, Inc. :DFFN-US: Earnings Analysis: Q1, 2016 By the Numbers : June 8, 2016 Capital Cube
06:07PM  Diffusion Pharmaceuticals, Inc. :DFFN-US: Earnings Analysis: Q1, 2016 By the Numbers : June 8, 2016
May-31-16 11:45AM  DFFN: Initiating Coverage of Diffusion Pharmaceuticals: Lead Compound Entering Phase 3 Clinical Trial in Brain Cancer Zacks Small Cap Research
11:45AM  DFFN: Initiating Coverage of Diffusion Pharmaceuticals: Lead Compound Entering Phase 3 Clinical Trial in Brain Cancer
Diffusion Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on developing products for ophthalmology, oncology, and dermatology. Its lead product candidate is transcrocetinate sodium, which is in Phase I/II clinical trials for re- oxygenating treatment-resistant tissue; and making the cancer cells more susceptible to the therapeutic effects of radiation therapy and chemotherapy. The company is also developing RES-529, a novel PI3K/Akt/mTOR pathway inhibitor, which has completed two Phase I clinical trials for the treatment of macular degeneration; and is in pre-clinical development in oncology applications primarily glioblastoma multiforme. In addition, it is developing RES-440, a soft anti-androgen compound for the treatment of acne vulgaris. The company is headquartered in Charlottesville, Virginia.